| Name | Title | Contact Details |
|---|
Norbrook® is a true innovator and dedicated to novel research and revolutionary processes and products. Lord Ballyedmond, Founder, Chairman and CEO of the Norbrook Group began his career in the pharmaceutical industry in the USA in the 1960s and now controls the largest privately owned pharmaceutical company in the world. The company is very active in both medical and veterinary products. Research and Development is the key to Norbrook`s success with the R&D Department central to the company`s structure. It is responsible for new product development, technical support and meeting regulatory and licensing protocols. Norbrook invests more than 10% of its turnover annually in research and development of new products. The company is at the forefront of formulation technology and has developed many new chemical routes for the synthesis of active materials. Norbrook has formulated and registered more than 800 products in 120 countries. The on-going success of the company is conditional on the expertise, knowledge and innovation of the staff employed. Norbrook prides itself on attracting the highest calibre of individual to the company and boasts a multi-national workforce committed to constantly pushing the boundaries and challenging technologies to ensure that Norbrook remains the leading force in pharmaceuticals that it is today.
MMS is an award-winning, global clinical research organization (CRO) that supports leading pharmaceutical and biotech companies as well as many smaller enterprises across our spectrum of services. Having completed more than 50 submissions for drug approval over the last 5 years, we remain a top choice for sponsors who are looking for innovation and demand high quality from their CRO partners. Senior leadership at MMS has more than two decades of hands-on drug development experience which helps support program-level strategy and execution of projects across multiple therapeutic areas. Continual staff training, innovative recruitment and motivating career opportunities help MMS retain the best talent and develop a strong, client-focused workforce across all global locations. Our mission is to deliver high-quality services, rooted in good science and decades of regulatory experience, that will assist our clients in developing and marketing life-changing therapies, thereby positively affecting patients` lives worldwide.
Myonexus Therapeutics is a clinical stage, rare disease gene therapy company developing first-ever, corrective treatments for Limb-girdle muscular dystrophy.
There are three Otsuka pharmaceutical industry companies in the U.S.: Otsuka America Pharmaceutical, Inc. (OAPI) successfully commercializes Otsuka-discovered and in-licensed products in North America. Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) clinically develops and registers innovative healthcare products on a global basis. Otsuka Maryland Medicinal Laboratories, Inc. (OMML) is a basic research center investigating pharmacological compounds.
U.S MAX HEALING PRODUCTS,INC is a Bellevue, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.